about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

US sells Wu-Tang Clan al­bum to cov­er Shkre­li debt; Or­biMed backs GSK vet­s' Chi­nese start­up

4 years ago
News Briefing

As­traZeneca castoff draws $123M wa­ger on CX­CR2 an­tag­o­nist as Are­na lines up a buy­out op­tion

4 years ago
Financing
Deals

Look­ing to repli­cate Covid-19 suc­cess in neu­ro, BioN­Tech back­ers bet on AC Im­mune and its new­ly-ac­quired Parkin­son's ...

4 years ago
Financing
Deals

Wav­ing off re­cent PhII flop, Bio­gen trum­pets ear­ly pos­i­tive Alzheimer's da­ta for an­ti-tau an­ti­sense

4 years ago
R&D

Chi­nese re­searcher — and for­mer 'fugi­tive' — re­turns home af­ter DOJ moves to drop a spate of cas­es

4 years ago
People
China

FDA un­sur­pris­ing­ly brings down the ham­mer on In­cyte's PD-1 — draw­ing a line for fu­ture ac­cel­er­at­ed ap­provals

4 years ago
FDA+

No­var­tis reshuf­fles its wild cards; Tough sell for Bio­gen? Googling pro­teins; Ken Fra­zier's new gig; and more

4 years ago
Weekly

Af­ter slic­ing and dic­ing TCRs for 8 years, Swedish biotech re­loads to an­gle for a spot in crowd­ed cell ther­a­py space

4 years ago
Financing
Cell/Gene Tx

As health­care heats up on HKEX, Qim­ing sets up $500M fund ded­i­cat­ed to pub­lic com­pa­nies

4 years ago
Financing
China

Af­ter chim­ing in an­ti­body to Covid-19 fight, Jun­shi drops $30M to kick off mR­NA joint ven­ture in Chi­na

4 years ago
Deals
China

Can a next-gen take on a dead­ly weight loss pill con­quer car­diometa­bol­ic dis­eases? A Medicxi-backed start­up thinks so

4 years ago
Financing
Startups

Gilead still has­n't made up its mind about Ar­cus' drugs, but there's a top ex­ec at the biotech it def­i­nite­ly wants

4 years ago
People

Mer­ck KGaA for­ti­fies its ‘site of the fu­ture’ with $319M re­search, staff train­ing cen­ters

4 years ago
Pharma

Bio­gen pressed against the wall as more stake­hold­ers side against Aduhelm; Prime time for CRISPR 3.0?; and more

4 years ago
Weekly

Celu­lar­i­ty emerges from SPAC merg­er dou­bled down on cell ther­a­pies as Bob Hariri down­grades ill-fat­ed Covid-19 ...

4 years ago
Deals
Cell/Gene Tx

Dis­cov­ery by Shang­hai sci­en­tists in­spires new plan of AT­TEC for pro­tein degra­da­tion

4 years ago
Financing
Startups

Cor­nered by crit­ics, top FDA of­fi­cials stand by Aduhelm OK amid calls to re­form ac­cel­er­at­ed ap­proval process

4 years ago
FDA+

Bap­tized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to car­ry on with pipeline for in­fec­tious dis­eases and ...

4 years ago
Financing
China

In search of a post-Tec­fidera hit for MS, Bio­gen fol­lows Sanofi, Roche down the BTK path — and bets $125M cash on a ...

4 years ago
Deals
China

Af­ter month­s­long lull, Big Phar­ma should be ready to pounce on M&A as mar­ket set­tles — an­a­lysts

4 years ago
Deals

Biden sets a 45-day count­down for 'com­pre­hen­sive' plan to tack­le drug pric­ing — while cham­pi­oning some fa­mil­iar ...

4 years ago
Pharma

Storm brews around Aduhelm as FDA re­quests probe; Dis­sect­ing pipeline dis­as­ters; Bob Nelsen is go­ing Re­al­ly Big; and ...

4 years ago
Weekly

As Pfiz­er/BioN­Tech prep EUA fil­ing for Covid-19 boost­er, FDA, CDC tell Amer­i­cans they don't need one just yet

4 years ago
FDA+
Coronavirus

In pur­suit of a block­buster, Am­gen and As­traZeneca score pri­or­i­ty re­view for asth­ma drug teze­pelum­ab

4 years ago
FDA+
First page Previous page 47484950515253 Next page Last page
A service from the Financial Times